Loading...
XBRU
TUB
Market cap7.04bUSD
Mar 06, Last price  
146.60EUR
1D
-1.87%
1Q
5.62%
Jan 2017
147.13%
Name

Financiere de Tubize SA

Chart & Performance

D1W1MN
No data to show
P/E
74.03
P/S
—
EPS
1.98
Div Yield, %
0.66%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
5.42%
Revenues
0k
-100.00%
2,00000000000001,000302,000004,000008,1510
Net income
88m
-49.40%
123,907,000293,857,000477,274,00039,534,000-905,000163,308,00020,868,00064,685,00077,812,00061,706,00060,845,000212,526,000181,186,000285,934,000285,156,000-1,095,000260,519,000380,090,000174,225,31288,151,267
CFO
-2m
-12,838,000327,964,0005,605,0005,322,000-12,794,000-1,121,000124,000-1,404,000-823,000-613,00063,449,00067,699,00072,962,00075,757,00079,778,00081,138,00084,024,000174,225,3120-2,069,000
Dividend
Apr 30, 20240.97 EUR/sh
Earnings
Aug 02, 2025

Profile

Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
URL
http://www.financiere-tubize.be/
IPO date
Jan 02, 1987
Employees
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8
 
Cost of revenue
2,078
1,882
Unusual Expense (Income)
NOPBT
(2,078)
(1,873)
NOPBT Margin
Operating Taxes
(89,055)
Tax Rate
NOPAT
(2,078)
87,182
Net income
88,151
-49.40%
174,225
-54.16%
Dividends
(43,176)
(38,281)
(33,380)
Dividend yield
1.20%
1.06%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
41,300
79,200
47,800
Long-term debt
Deferred revenue
453
Other long-term liabilities
Net debt
39,871
78,625
(1,790,956)
Cash flow
Cash from operating activities
(2,069)
174,225
CAPEX
Cash from investing activities
87,270
11,299
(5,713)
Cash from financing activities
(84,346)
(9,747)
(7,008)
FCF
3,662
2,928
124,996
Balance
Cash
1,429
575
1,069
Long term investments
1,837,687
Excess cash
1,429
575
1,838,756
Stockholders' equity
370,051
1,772,639
1,752,845
Invested Capital
1,880,276
1,876,155
46,999
ROIC
11.21%
ROCE
EV
Common stock shares outstanding
44,513
44,513
Price
142.20
98.33%
71.70
1.27%
70.80
-21.59%
Market cap
3,191,553
1.27%
3,151,492
-21.59%
EV
3,270,178
1,360,536
EBITDA
(2,078)
(1,873)
EV/EBITDA
Interest
2,063
Interest/NOPBT